Navigation Links
New Survey Reveals High Expectations for Popular Aesthetic Injections

SCOTTSDALE, Ariz., July 7 /PRNewswire/ -- Americans aren't willing to give up aesthetic injections and interest is growing, whether as a means to stay competitive in today's job market or simply to maintain a youthful image, the demand and want is strong. At the time of a recent Kelton Research* survey more than 40 percent of respondents were interested in receiving aesthetic botulinum toxin injections within the next six months.(1)

Despite clear interest, many expressed reluctance to having a botulinum toxin injection. In fact, one-third of those who had not yet received the treatment were worried that it would prevent them from being able to make natural facial expressions.(1)

Sixty-three percent of survey respondents who would ever consider receiving botulinum toxin injections cited that a guarantee of natural-looking results would influence their decision, demonstrating a desire for retaining a natural-looking face, and more natural-looking expressions following injection.(1) Other top factors included more affordable costs, longer-lasting and faster-acting results.(2)

The poll found that of the respondents who had never undergone botulinum toxin injections, 36% said that their concern about no longer having a natural look had prevented them from receiving the treatment in the past.(1) Almost 60 percent of those surveyed who had not ever received an injection stated that they'd be likely to if the cost of treatment was more affordable.(1) And, of the respondents who had botulinum toxin injections, three in ten reported not seeing noticeable results for at least a week(1) and thirty percent of polled respondents said that having immediate results, such as within 24-48 hours, would positively influence their decision to undergo treatment.(2)

According to Florida dermatologist Dr. Susan Weinkle, patients want value and rapid results at a fair price. "My patients are looking for a treatment that will not make them look obvious or overdone and they want these natural looking results fast."

They are in luck: after extensive testing and clinical results, a new Botulinum Toxin A is now on the market. Dysport(TM) has been approved by the FDA for use in the United States for the temporary improvement in the appearance of moderate to severe glabellar lines - the vertical lines between the eyebrows - in adult men and women 65 or younger.

The benefits of Dysport(TM) include:

  • Duration - results lasting up to four months
  • Demonstrated efficacy with four repeat treatments (proving results following each treatment)
  • Demonstrated safety with 12 repeat treatments
  • No evidence of neutralizing antibodies
  • Clinical trials included both subjects who have and have not previously been treated with a Botulinum Toxin. There was no difference in results among the two groups
  • Large patient population - 4,800 treatments in 2,900 patients (with an ethnically diverse population)

*About the 2009 Botulinum Toxin survey:

Sample: 600 U.S. adults ages 25-60 with a household income of $50,000 or more, including 570 females and 300 botulinum toxin users and 300 aware of at least one nonsurgical aesthetic procedure or treatment.(2)


1. Kelton Research. Botulinum Toxin Survey NewsWorthy Analysis. February--March 2009. Data on file, Medicis Pharmaceutical Corporation.

2. Kelton Research. Botulinum Toxin Survey Topline Report. February--March 2009. Data on file, Medicis Pharmaceutical Corporation.

Important Safety Information

Dysport(TM) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in appearance of moderate to

severe glabellar lines associated with procerus and corrugator muscle activity in adult patients.

Botulinum toxin effects may spread beyond the site of local injection to produce systemic symptoms of botulism such as swallowing and breathing difficulties that can occur within hours to weeks of injection. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults, particularly in those patents who have underlying conditions that would predispose them to these symptoms. In clinical trials, the most frequently reported adverse effects (>2%) are headache, nasopharyngitis and upper respiratory tract infection.

Dysport(TM) is not recommended for children or pregnant women. Re-treatment with Dysport(TM) should be administered no more than every three months.

SOURCE Medicis Aesthetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NEUTROGENA(R) and BabyCenter Sun Survey Finds While Mom Knows Best She Can Learn Even More When it Comes to Sun Protection
2. National Survey Shows 70% of Women Have Experienced a Sexual Health Issue
3. CED/Zogby Release Survey of Business Perspectives on Healthcare Reform
4. Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
5. SouthWest Benefits Association Survey Finds Employers Continue to Focus on Health and Wellness during Economic Downturn
6. Innoventz Certified to Score Both the SF-36v2 and SF-12v2 Health Surveys
7. Snoring Isn't Sexy, LLC Launches Survey to Determine Extent of Drowsy Drivers on Land, Sea and In The Air
8. CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting
9. Survey Reveals That Body Insecurity Prevents Nearly Half (49%) of Americans From Engaging in Summer Activities
10. Recent Survey Suggests Complications with Permanent Fillers
11. URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies
Post Your Comments:
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology: